Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $111,300 | 7 | 99.8% |
| Food and Beverage | $230.45 | 7 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ChiRhoClin, Inc. | $111,300 | 7 | $0 (2019) |
| ABBVIE INC. | $84.02 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $65.20 | 1 | $0 (2023) |
| Promega Corporation | $58.72 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.51 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.97 | 1 | ABBVIE INC. ($20.97) |
| 2023 | $110.87 | 3 | AstraZeneca Pharmaceuticals LP ($65.20) |
| 2022 | $76.10 | 2 | Promega Corporation ($58.72) |
| 2020 | $22.51 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($22.51) |
| 2019 | $12,600 | 1 | ChiRhoClin, Inc. ($12,600) |
| 2018 | $48,300 | 3 | ChiRhoClin, Inc. ($48,300) |
| 2017 | $50,400 | 3 | ChiRhoClin, Inc. ($50,400) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: IMMUNOLOGY | ||||||
| 06/12/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: IMMUNOLOGY | ||||||
| 04/20/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $65.20 | General |
| 01/26/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2022 | Promega Corporation | — | Food and Beverage | In-kind items and services | $58.72 | General |
| 10/06/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/29/2019 | ChiRhoClin, Inc. | ChiRhoStim (Drug) | — | In-kind items and services | $12,600.00 | Research |
| Study: CAPS 5 • Category: Diagnostic | ||||||
| 10/30/2018 | ChiRhoClin, Inc. | ChiRhoStim (Human Secretin) (Drug) | — | In-kind items and services | $18,900.00 | Research |
| Study: CAPS 5 • Category: Diagnostic | ||||||
| 08/07/2018 | ChiRhoClin, Inc. | ChiRhoStim (Human Secretin) (Drug) | — | In-kind items and services | $10,500.00 | Research |
| Study: CAPS 5 • Category: Diagnostic | ||||||
| 04/02/2018 | ChiRhoClin, Inc. | ChiRhoStim (Human Secretin) (Drug) | — | In-kind items and services | $18,900.00 | Research |
| Study: CAPS 5 • Category: Diagnostic | ||||||
| 11/15/2017 | ChiRhoClin, Inc. | ChiRhoStim Human Secretin for Injection (Drug) | — | In-kind items and services | $18,900.00 | Research |
| Study: The Cancer of the Pancreas Screening-5 CAPS5 • Category: Diagnostic | ||||||
| 07/05/2017 | ChiRhoClin, Inc. | ChiRhoStim Human Secretin for Injection (Drug) | — | In-kind items and services | $18,900.00 | Research |
| Study: The Cancer of the Pancreas Screening-5 CAPS5 • Category: Diagnostic | ||||||
| 02/22/2017 | ChiRhoClin, Inc. | ChiRhoStim Human Secretin for Injection (Drug) | — | In-kind items and services | $12,600.00 | Research |
| Study: The Cancer of the Pancreas Screening-5 CAPS5 • Category: diagnostic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CAPS 5 | ChiRhoClin, Inc. | $60,900 | 4 |
| The Cancer of the Pancreas Screening-5 CAPS5 | ChiRhoClin, Inc. | $50,400 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 247 | 263 | $141,115 | $26,257 |
| 2022 | 7 | 226 | 245 | $137,174 | $26,112 |
| 2021 | 12 | 290 | 329 | $169,034 | $35,987 |
| 2020 | 11 | 254 | 290 | $145,783 | $28,616 |
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 64 | $14,208 | $5,809 | 40.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 26 | 26 | $32,552 | $5,055 | 15.5% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 22 | 22 | $19,822 | $3,246 | 16.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $11,418 | $2,915 | 25.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 18 | 18 | $15,984 | $2,034 | 12.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 38 | 38 | $27,816 | $1,865 | 6.7% |
| 43237 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | Facility | 2023 | 12 | 12 | $8,388 | $1,727 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 25 | $3,725 | $1,458 | 39.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $4,760 | $1,414 | 29.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,442 | $734.72 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 59 | 78 | $17,316 | $6,850 | 39.6% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $20,723 | $3,983 | 19.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 17 | 17 | $20,658 | $3,304 | 16.0% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $16,367 | $2,688 | 16.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $8,304 | $2,252 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 34 | $5,066 | $2,213 | 43.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 11 | 11 | $13,772 | $2,097 | 15.2% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 12 | 12 | $10,812 | $1,560 | 14.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $13,176 | $765.46 | 5.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 15 | 15 | $10,980 | $398.12 | 3.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 31 | 31 | $38,812 | $6,127 | 15.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 59 | $13,098 | $5,681 | 43.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 34 | 34 | $11,764 | $4,211 | 35.8% |
| 43259 | Ultrasound examination of esophagus, stomach and/or upper small bowel using an endoscope | Office | 2021 | 24 | 24 | $21,624 | $3,878 | 17.9% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 17 | 18 | $22,662 | $3,773 | 16.6% |
About Randall Brand
Randall Brand is a Gastroenterology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255361184.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Randall Brand has received a total of $111,530 in payments from pharmaceutical and medical device companies, with $20.97 received in 2024. These payments were reported across 14 transactions from 5 companies. The most common payment nature is "" ($111,300).
As a Medicare-enrolled provider, Brand has provided services to 1,017 Medicare beneficiaries, totaling 1,127 services with total Medicare billing of $116,972. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Pittsburgh, PA
- Active Since 07/04/2006
- Last Updated 03/25/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1255361184
Products in Payments
- ChiRhoStim Human Secretin for Injection (Drug) $50,400
- ChiRhoStim (Human Secretin) (Drug) $48,300
- ChiRhoStim (Drug) $12,600
- RINVOQ (Biological) $43.62
- SKYRIZI (Biological) $40.40
- ENTYVIO (Biological) $22.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Pittsburgh
Dr. Sandra El-Hachem, Md, MD
Gastroenterology — Payments: $416,688
Elie Aoun, M.d., M.s, M.D., M.S
Gastroenterology — Payments: $358,981
Dr. Michael Babich, Md, MD
Gastroenterology — Payments: $154,891
Gursimran Kochhar, Md, MD
Gastroenterology — Payments: $109,305
Dr. Heitham Abdul-Baki, M.d, M.D
Gastroenterology — Payments: $67,965
Dr. Katie Farah, Md, MD
Gastroenterology — Payments: $60,366